704209-22-3

Basic information

• Product Name: [1,1-Bicyclopentyl]-2-amine,(1R,2R)-(9CI)
• Synonyms: [1,1-Bicyclopentyl]-2-amine,(1R,2R)-(9CI)
• CAS NO: 704209-22-3
• Molecular Formula: C10H19N
• Molecular Weight: 0
• Product Categories: CYCLOPENTANE
• Mol File: 704209-22-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [1,1-Bicyclopentyl]-2-amine,(1R,2R)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: [1,1-Bicyclopentyl]-2-amine,(1R,2R)-(9CI)(704209-22-3)
• EPA Substance Registry System: [1,1-Bicyclopentyl]-2-amine,(1R,2R)-(9CI)(704209-22-3)

Safety Data

• Hazardous Substances Data: 704209-22-3(Hazardous Substances Data)

Usage

General Description

[1,1-Bicyclopentyl]-2-amine,(1R,2R)-(9CI) is a chemical compound with a unique structure containing a bicyclopentyl ring and an amine group. It is also referred to as (1R,2R)-bicyclo[1.1.1]pentane-1,2-diamine. This chemical has stereochemistry designated as (1R,2R) and is often used in research and pharmaceutical applications. Its specific properties and potential uses may vary, and further studies are required to fully understand its potential applications and effects.

Upstream product

• 4884-25-7 2-cyclopentylcyclopentanol 
• 2866-71-9 (1,1'-bicyclopentyl)-2-one 
• 64-17-5 ethanol 
• 99188-59-7 bicyclopentyl-2-one oxime 
• 64-19-7 acetic acid 
• 5834-10-6 bicyclopentyliden-2-one oxime 

Downstream Products

• 61423-37-8 cis-2-acetylamino-bicyclopentyl 
• 61423-37-8 trans-2-acetylamino-bicyclopentyl 
• 61423-35-6 cis-2-Benzamino-bicyclopentyl 
• 61423-35-6 trans-2-Benzamino-bicyclopentyl 

Relevant articles and documents

The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1- hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist

The optimisation of two series of 4-hydroxybenzothiazolone derived β2-adrenoceptor agonists, bearing α-substituted cyclopentyl and β-phenethyl amino-substituents, as inhaled long-acting bronchodilators is described. Analogues were selected for synthesis using a lipophilicity based hypothesis to achieve the targeted rapid onset of action in combination with a long duration of action. The profiling of the two series led to identification of the α-substituted cyclopentyl analogue 2 as the optimal compound with a comparable profile to the inhaled once-daily long-acting β2-adrenoceptor agonist indacaterol. On the basis of these data 2 was promoted as the backup development candidate to indacaterol from the Novartis LABA project.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).